Activation of peroxisome proliferator-activated receptor γ ameliorates monocrotaline-induced pulmonary arterial hypertension in rats

Xie,Xinming; Wang,Guizuo; Zhang,Dexin; Zhang,Yonghong; Zhu,Yanting; Li,Fangwei; Li,Shaojun; Li,Manxiang

doi:10.3892/br.2015.465

Activation of peroxisome proliferator-activated receptor γ ameliorates monocrotaline-induced pulmonary arterial hypertension in rats

Authors:
- Xinming Xie
- Guizuo Wang
- Dexin Zhang
- Yonghong Zhang
- Yanting Zhu
- Fangwei Li
- Shaojun Li
- Manxiang Li
View Affiliations

Affiliations: Department of Respiratory Medicine, The First Affiliated Hospital of Medical College, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China, Department of Respiratory Medicine, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi 710068, P.R. China
Published online on: May 21, 2015 https://doi.org/10.3892/br.2015.465
Pages: 537-542

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Activation of peroxisome proliferator-activated receptor γ (PPARγ) suppresses the proliferation of pulmonary artery smooth muscle cells (PASMCs) and vascular remodeling in rats and humans, and therefore improves the development of pulmonary arterial hypertension (PAH). However, molecular mechanisms underlying these effects have not been completely understood. In the present study, the effects of PPARγ activation in monocrotaline (MCT)‑induced pulmonary artery remodeling in rats were investigated. Eighteen Sprague‑Dawley (SD) rats were randomly assigned into three groups (n=6): Control (Con), PAH and PAH treated with rosiglitazone (MCT + Rosi). The right ventricular systolic pressure (RVSP), the ratio of the right to left ventricle plus septum weight [RV/(LV + S)], the percentage of medial wall thickness (%MT) and wall area (%WA) were used to evaluate the development of PAH. Tissue morphology was measured using hematoxylin and eosin staining. The protein levels of the phosphatase and tensin homologue deleted on chromosome ten (PTEN), Akt (ser473) phosphorylation (p‑Akt) and total Akt in intrapulmonary arteries were determined by western blot analysis. MCT treatment significantly increased the RVSP, which was reduced by rosiglitazone treatment. The ratio of RV/(LV + S), %MT and %WA induced by MCT were similarly inhibited, which was associated with the increase of PTEN expression and the inhibition of Akt phosphorylation levels by rosiglitazone. In conclusion, activation of PPARγ ameliorates the proliferation of PASMCs and vascular remodeling by regulating the PTEN/PI3K/Akt pathway, suggesting that the activation of PPARγ has potential benefits for PAH.

View Figures

View References

1	Humbert M, Sitbon O and Simonneau G: Treatment of pulmonary arterial hypertension. N Engl J Med. 351:1425–1436. 2004. View Article : Google Scholar : PubMed/NCBI
2	Martens FM, Visseren FL, Lemay J, de Koning EJ and Rabelink TJ: Metabolic and additional vascular effects of thiazolidinediones. Drugs. 62:1463–1480. 2002. View Article : Google Scholar : PubMed/NCBI
3	Meng Y, Chen C, Tian C, Du J and Li HH: Angiotensin II-induced Egr-1 expression is suppressed by peroxisome proliferator-activated receptor-γ ligand 15d-PGJ2 in macrophages. Cell Physiol Biochem. 35:689–698. 2015. View Article : Google Scholar : PubMed/NCBI
4	Gao D, Hao G, Meng Z, et al: Rosiglitzone Suppresses Angiotensin II-Induced Production of KLF5 and Cell Proliferation in Rat Vascular Smooth Muscle Cells. PLoS One. 10:e01237242015. View Article : Google Scholar : PubMed/NCBI
5	Nicola T, Ambalavanan N, Zhang W, et al: Hypoxia-induced inhibition of lung development is attenuated by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone. Am J Physiol Lung Cell Mol Physiol. 301:L125–134. 2011. View Article : Google Scholar : PubMed/NCBI
6	Jiang C, Ting AT and Seed B: PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature. 391:82–86. 1998. View Article : Google Scholar : PubMed/NCBI
7	Morales-Garcia JA, Luna-Medina R, Alfaro-Cervello C, Cortes-Canteli M, Santos A, Garcia-Verdugo JM and Perez-Castillo A: Peroxisome proliferator-activated receptor γ ligands regulate neural stem cell proliferation and differentiation in vitro and in vivo. Glia. 59:293–307. 2011. View Article : Google Scholar : PubMed/NCBI
8	Kulkarni AA, Thatcher TH, Olsen KC, Maggirwar SB, Phipps RP and Sime PJ: PPAR-γ ligands repress TGFβ-induced myofibroblast differentiation by targeting the PI3K/Akt pathway: Implications for therapy of fibrosis. PLoS One. 6:e159092011. View Article : Google Scholar : PubMed/NCBI
9	Nisbet RE, Bland JM, Kleinhenz DJ, Mitchell PO, Walp ER, Sutliff RL and Hart CM: Rosiglitazone attenuates chronic hypoxia-induced pulmonary hypertension in a mouse model. Am J Respir Cell Mol Biol. 412:482–490. 2010. View Article : Google Scholar
10	Ochoa CD, Yu L, Al-Ansari E, Hales CA and Quinn DA: Thrombospondin-1 null mice are resistant to hypoxia-induced pulmonary hypertension. J Cardiothorac Surg. 5:322010. View Article : Google Scholar : PubMed/NCBI
11	Wang LX, Sun Y, Chen C, Huang XY, Lin Q, Qian GQ, Dong W and Chen YF: Effects and mechanism of oridonin on pulmonary hypertension induced by chronic hypoxia-hypercapnia in rats. Chin Med J (Engl). 122:1380–1387. 2009.PubMed/NCBI
12	Ismail S, Sturrock A, Wu P, Cahill B, Norman K, Huecksteadt T, Sanders K, Kennedy T and Hoidal J: NOX4 mediates hypoxia-induced proliferation of human pulmonary artery smooth muscle cells: The role of autocrine production of transforming growth factor-{β}1 and insulin-like growth factor binding protein-3. Am J Physiol Lung Cell Mol Physiol. 296:L489–L499. 2009. View Article : Google Scholar : PubMed/NCBI
13	Zhang D, Ma C, Li S, Ran Y, Chen J, Lu P, Shi S and Zhu D: Effect of Mitofusin 2 on smooth muscle cells proliferation in hypoxic pulmonary hypertension. Microvasc Res. 84:286–296. 2012. View Article : Google Scholar : PubMed/NCBI
14	Goncharova EA, Ammit AJ, Irani C, Carroll RG, Eszterhas AJ, Panettieri RA and Krymskaya VP: PI3K is required for proliferation and migration of human pulmonary vascular smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 283:L354–L363. 2002. View Article : Google Scholar : PubMed/NCBI
15	Fenton TR, Nathanson D, Ponte de Albuquerque C, Kuga D, Iwanami A, Dang J, Yang H, Tanaka K, Oba-Shinjo SM, Uno M, et al: Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240. Proc Natl Acad Sci USA. 109:14164–14169. 2012. View Article : Google Scholar : PubMed/NCBI
16	Ying H, Elpek KG, Vinjamoori A, Zimmerman SM, Chu GC, Yan H, Fletcher-Sananikone E, Zhang H, Liu Y, Wang W, et al: PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network. Cancer Discov. 1:158–169. 2011. View Article : Google Scholar : PubMed/NCBI
17	Zhang JG, Wang JJ, Zhao F, Liu Q, Jiang K and Yang GH: MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin Chim Acta. 411:846–852. 2010. View Article : Google Scholar : PubMed/NCBI
18	Oudit GY and Penninger JM: Cardiac regulation by phosphoinositide 3-kinases and PTEN. Cardiovasc Res. 82:250–260. 2009. View Article : Google Scholar : PubMed/NCBI
19	Oudit GY, Sun H, Kerfant BG, Crackower MA, Penninger JM and Backx PH: The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J Mol Cell Cardiol. 37:449–471. 2004. View Article : Google Scholar : PubMed/NCBI
20	Chen L, Monti S, Juszczynski P, Ouyang J, Chapuy B, Neuberg D, Doench JG, Bogusz AM, Habermann TM, Dogan A, et al: SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas. Cancer Cell. 23:826–838. 2013. View Article : Google Scholar : PubMed/NCBI
21	De Luca A, Maiello MR, D'Alessio A, Pergameno M and Normanno N: The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: Role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets. 16:(Suppl 2). S17–S27. 2012. View Article : Google Scholar : PubMed/NCBI
22	Moon SH, Kim DK, Cha Y, Jeon I, Song J and Park KS: PI3K/Akt and Stat3 signaling regulated by PTEN control of the cancer stem cell population, proliferation and senescence in a glioblastoma cell line. Int J Oncol. 42:921–928. 2013.PubMed/NCBI
23	Conley-LaComb MK, Saliganan A, Kandagatla P, Chen YQ, Cher ML and Chinni SR: PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling. Mol Cancer. 12:852013. View Article : Google Scholar : PubMed/NCBI
24	Akca H, Demiray A, Aslan M, Acikbas I and Tokgun O: Tumour suppressor PTEN enhanced enzyme activity of GPx, SOD and catalase by suppression of PI3K/AKT pathway in non-small cell lung cancer cell lines. J Enzyme Inhib Med Chem. 28:539–544. 2013. View Article : Google Scholar : PubMed/NCBI
25	Kitagishi Y and Matsuda S: Redox regulation of tumor suppressor PTEN in cancer and aging (Review). Int J Mol Med. 31:511–515. 2013.PubMed/NCBI
26	Monsalve FA, Pyarasani RD, Delgado-Lopez F and Moore-Carrasco R: Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases. Mediators Inflamm. 2013:5496272013. View Article : Google Scholar : PubMed/NCBI
27	Nickkho-Amiry M, McVey R and Holland C: Peroxisome proliferator-activated receptors modulate proliferation and angiogenesis in human endometrial carcinoma. Mol Cancer Res. 10:441–453. 2012. View Article : Google Scholar : PubMed/NCBI
28	O'Sullivan SE and Kendall DA: Cannabinoid activation of peroxisome proliferator-activated receptors: Potential for modulation of inflammatory disease. Immunobiology. 215:611–616. 2010. View Article : Google Scholar : PubMed/NCBI
29	Robinson E and Grieve DJ: Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease. Pharmacol Ther. 122:246–263. 2009. View Article : Google Scholar : PubMed/NCBI
30	Stephen J, Delvecchio C, Spitale N, Giesler A, Radford K, Bilan P, Cox PG, Capone JP and Nair P: PPAR ligands decrease human airway smooth muscle cell migration and extracellular matrix synthesis. Eur Respir J. 41:425–432. 2013. View Article : Google Scholar : PubMed/NCBI
31	Wang H, Wu Q, Liu Z, Luo X, Fan Y, Liu Y, Zhang Y, Hua S, Fu Q, Zhao M, et al: Downregulation of FAP suppresses cell proliferation and metastasis through PTEN/PI3K/AKT and Ras-ERK signaling in oral squamous cell carcinoma. Cell Death Dis. 5:e11552014. View Article : Google Scholar : PubMed/NCBI
32	Crossno JT Jr, Garat CV, Reusch JE, Morris KG, Dempsey EC, McMurtry IF, Stenmark KR and Klemm DJ: Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling. Am J Physiol Lung Cell Mol Physiol. 292:L885–L897. 2007. View Article : Google Scholar : PubMed/NCBI
33	Zhang D, Wang G, Han D, Zhang Y, Xu J, Lu J, Li S, Xie X, Liu L, Dong L, et al: Activation of PPAR-γ ameliorates pulmonary arterial hypertension via inducing heme oxygenase-1 and p21(WAF1): An in vivo study in rats. Life Sci. 98:39–43. 2014. View Article : Google Scholar : PubMed/NCBI
34	Nicol CJ, Adachi M, Akiyama TE and Gonzalez FJ: PPARgamma in endothelial cells influences high fat diet-induced hypertension. Am J Hypertens. 18:549–556. 2005. View Article : Google Scholar : PubMed/NCBI
35	Hansmann G, de Jesus Perez VA, Alastalo TP, Alvira CM, Guignabert C, Bekker JM, Schellong S, Urashima T, Wang L, Morrell NW, et al: An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension. J Clin Invest. 118:1846–1857. 2008. View Article : Google Scholar : PubMed/NCBI
36	Lu X, Bijli KM, Ramirez A, Murphy TC, Kleinhenz J and Hart CM: Hypoxia downregulates PPARγ via an ERK1/2-NF-κB-Nox4-dependent mechanism in human pulmonary artery smooth muscle cells. Free Radic Biol Med. 63:151–160. 2013. View Article : Google Scholar : PubMed/NCBI
37	Liu Y, Tian XY, Huang Y and Wang N: Rosiglitazone Attenuated Endothelin-1-Induced Vasoconstriction of Pulmonary Arteries in the Rat Model of Pulmonary Arterial Hypertension via Differential Regulation of ET-1 Receptors. PPAR Res. 2014:3740752014. View Article : Google Scholar : PubMed/NCBI
38	Kang BY, Park KK, Green DE, Bijli KM, Searles CD, Sutliff RL and Hart CM: Hypoxia mediates mutual repression between microRNA-27a and PPARγ in the pulmonary vasculature. PLoS One. 8:e795032013. View Article : Google Scholar : PubMed/NCBI